News
EVMN
8.35
-0.48%
-0.04
Weekly Report: what happened at EVMN last week (0921-0925)?
Weekly Report · 2d ago
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
TipRanks · 6d ago
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Benzinga · 6d ago
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301
Seeking Alpha · 09/22 10:05
Weekly Report: what happened at EVMN last week (0914-0918)?
Weekly Report · 09/21 10:28
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF)
TipRanks · 09/18 11:50
Evommune updates pipeline and market outlook in presentation
TipRanks · 09/15 13:00
Weekly Report: what happened at EVMN last week (0907-0911)?
Weekly Report · 09/14 10:34
Evommune price target lowered to $23 from $28 at Clear Street
TipRanks · 09/09 23:50
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 09/09 17:06
Evommune Price Target Cut to $22.00/Share From $28.00 by Leerink Partners
Dow Jones · 09/09 16:03
Evommune Is Maintained at Outperform by Leerink Partners
Dow Jones · 09/09 16:03
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
Benzinga · 09/09 15:54
Stifel Nicolaus Remains a Buy on Evommune, Inc. (EVMN)
TipRanks · 09/09 14:35
Analysts Are Bullish on These NA Stocks: Douglas AG (DOUDF), Evommune, Inc. (EVMN)
TipRanks · 09/09 13:50
Evommune Price Target Cut to $21.00/Share From $29.00 by RBC Capital
Dow Jones · 09/09 13:43
Evommune Is Maintained at Outperform by RBC Capital
Dow Jones · 09/09 13:43
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
Benzinga · 09/09 13:33
Evommune price target lowered to $18 from $32 at Raymond James
TipRanks · 09/09 12:55
Evommune price target lowered to $22 from $28 at Leerink
TipRanks · 09/09 12:40
More
Webull provides a variety of real-time EVMN stock news. You can receive the latest news about EVOMMUNE INC through multiple platforms. This information may help you make smarter investment decisions.
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.